FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts

FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts

Abstract Group 3 tumors account for 28% of medulloblastomas and have the worst prognosis. FTY720, an immunosuppressant currently approved for treatment of multiple sclerosis, has shown antitumor effects in several human cancer cell lines. We hypothesized that treatment with FTY720 (fingolimod) would...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Evan F. Garner, Adele P. Williams, Laura L. Stafman, Jamie M. Aye, Elizabeth Mroczek-Musulman, Blake P. Moore, Jerry E. Stewart, Gregory K. Friedman, Elizabeth A. Beierle
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/60d3b17a2b504ab498e8b0462588e830
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares